After signing up, you'll start to receive regular news updates from us.
AION Diagnostics Announces BioSilicon™
Complete the form below to unlock access to ALL audio articles.
pSivida Limited has announced that its wholly owned US subsidiary, AION Diagnostics Inc. has discovered a property to its nanotechnology platform, BioSilicon™.
The biomaterial has been shown to be effectively visualized on four key imaging modalities; x-ray, ultrasound, CT and MRI.
"The discovery of BioSilicon’s™ unique property in imaging has identified a key competitive advantage since previously only combinations of materials could achieve these properties," said Dr. Anna Kluczewska, President and Chief Executive Officer of AION Diagnostics Inc.
"The discovery marks an important milestone in AION’S development and the imaging sector as a whole by bringing new properties of nanomaterials to diagnosis and preventative medicine."
AION’s strategy includes spinning off early-to-revenue products while developing its molecular imaging product line.
This discovery allows AION to begin development in the following areas:
Tissue Marker Products
AION’s Tissue Marker portfolio of potential products is expected to be used for marking of biopsy sites and monitoring and guiding cancer therapeutic regimes.
Advantages of this BioSilicon™ based technology are that the Markers can be visualized by any key imaging modality and that biodegradation time can be engineered to optimize clinical requirements for visualization and spatial enhancement of pathology.
The first of these products are expected to be approved in 2008.
The FDA has indicated a 510(K) device registration path to approval for the first Tissue Marker products, with subsequent indications to be filed shortly after.
"We believe that the unique properties we have discovered allow AION to target multiple indications and product areas with a single formulation," says Dr. Kluczewska.
